Should we discontinue RAS-inhibitor therapy in patients with advanced CKD?

Panagiotis I Georgianos; Vasilios Vaios; Maria Divani; Vassilios Liakopoulos

doi:10.1080/14656566.2023.2207738

Should we discontinue RAS-inhibitor therapy in patients with advanced CKD?

Expert Opin Pharmacother. 2023 Jun;24(9):977-980. doi: 10.1080/14656566.2023.2207738. Epub 2023 Apr 28.

Authors

Panagiotis I Georgianos¹, Vasilios Vaios¹, Maria Divani², Vassilios Liakopoulos¹

Affiliations

¹ Department of Nephrology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
² Hemodialysis Unit, General Hospital of Larissa, Larissa, Greece.

PMID: 37185138
DOI: 10.1080/14656566.2023.2207738

No abstract available

Keywords: Angiotensin converting enzyme inhibitors; RAS-blockade; advanced CKD; angiotensin receptor blockers; dialysis; hyperkalemia; kidney failure.

Publication types

Editorial
Comment

MeSH terms

Angiotensin-Converting Enzyme Inhibitors*
Humans
Renal Insufficiency, Chronic* / drug therapy
Renin-Angiotensin System

Substances

Angiotensin-Converting Enzyme Inhibitors